A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00587587|
Recruitment Status : Completed
First Posted : January 7, 2008
Results First Posted : August 19, 2011
Last Update Posted : August 19, 2011
|Condition or disease||Intervention/treatment||Phase|
|Keloid||Device: Apligraf Other: Standard dressing regimen||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective, Randomized, Controlled Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids|
|Study Start Date :||December 2007|
|Actual Primary Completion Date :||March 2010|
|Actual Study Completion Date :||March 2010|
Apligraf (bilayered living cell therapy)
Application at Day 0, potential re-application at Week 4
Active Comparator: B
Dressing regimen comprised of a primary nonadherent dressing, dry gauze dressing and bolster gauze dressing, if necessary
Other: Standard dressing regimen
A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
- The Primary Purpose of This Study Will be to Gain Preliminary Safety Experience With Apligraf in the Keloid Indication. The Number of Participants Experiencing AEs is Presented. [ Time Frame: 52 weeks ]
Summary of all reported adverse events (AE) in the intent to treat (ITT) population.
AE was defined as any adverse change in the subject's medical status compared with the subject's baseline condition, whether or not the event was related to the study device or a study procedure; or an exacerbation (either in frequency or severity) in a subject's pre-existing condition. AE data were collected at every study visit or if volunteered by the subject at any time during the study.
- Change in Degree of Keloid Recurrence as Measured by Beausang Scar Scale (BSS) [ Time Frame: Baseline to Week 52 or Last Visit ]
Change in BSS cumulative score, Baseline to Last Visit, as reported by the Investigator, is reported.
BSS is a composite score where the individual scores from the following categories are summed:
Color (rated 1[perfect]-4[gross mismatch]), Shine (1/Matte or 2/Shiny), Contour (rated 1[flush with surrounding skin]-4[keloid]), Distortion (rated 1[None]-4[severe]), Texture (rated 1[normal]-4[hard]), and Overall Assessment on a 10cm visual analog scale (rated 0[excellent scar]-10 [poor scar]).
Total score ranges from 5 (clinically well healed scar) - 28 (clinically poor scar).
- Cumulative Incidence of Keloid Recurrence at Week 52 [ Time Frame: 52 weeks ]Recurrence is defined the first study visit at which the Investigator scores the Contour component of the BSS with a 4 (indicating a keloid). Contour is one of the five components measured in the BSS with Contour scores ranging from 1 (flush with surrounding skin) to 4 (keloid). Recurrence is a negative outcome.
- Degree of Recurrence (Scar Firmness) [ Time Frame: Week 52 or Last Visit ]Scar firmness measured by Cutometer in millimeters.
- Degree of Recurrence (Scar Thickness) [ Time Frame: Week 52 or Last visit ]Scar thickness measured by slide caliper in millimeters. A value of 0.0 mm on the slide caliper is equivalent to normal, non-hypertrophic/raised skin.
- Physician Global Assessment [ Time Frame: Week 52 or Last Visit ]Investigator assessed using 5 point scale (1-excellent, 2-very good, 3-good, 4-moderate, 5-poor)
- Subject Global Assessment [ Time Frame: Week 52 or Last Visit ]Subject assessed using 5 point scale (1-excellent, 2-very good, 3-good, 4-moderate, 5-poor)
- Decreased Utilization of Intralesional Steroid Intervention [ Time Frame: 52 weeks ]The mean number of Intralesional (IL) Injections per participant is reported. A lower number of injections is a better outcome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00587587
|United States, Florida|
|University of Miami, Miller School of Medicine, Division of Cosmetic Dermatology|
|Miami Beach, Florida, United States, 33140|
|Principal Investigator:||Heather Woolery-Lloyd, MD||University of Miami, Miller School of Medicine, Division of Cosmetic Dermatology|
|Study Director:||Damien Bates, MD, PhD, FRACS (Plast.)||Organogenesis Inc.|